Literature DB >> 29555332

Vulvar cancer: Two pathways with different localization and prognosis.

F Hinten1, A Molijn2, L Eckhardt3, L F A G Massuger3, W Quint2, P Bult4, J Bulten4, W J G Melchers5, J A de Hullu3.   

Abstract

BACKGROUND: Two etiologic pathways for vulvar squamous cell carcinoma (SCC) are described: in a background of lichen sclerosus and/or differentiated vulvar intraepithelial neoplasia and related to high-risk human papillomavirus (HPV) infection with high grade squamous intraepithelial lesion (HSIL) as precursor. The aim was to compare the predilection site and survival of HPV-related to non HPV-related vulvar SCCs.
METHODS: Data of patients treated for primary vulvar SCC at the Radboudumc between March 1988 and January 2015 were analyzed. All histological specimens were tested for HPV with the SPF10/DEIA/LiPA25 system assay and p16INK4a staining was performed using CINtec® histology kit. Vulvar SCCs were considered HPV-related in case of either >25% p16INK4a expression and HPV positivity or >25% p16INK4a expression and HSIL next to the tumor without HPV positivity. Tumor localization, disease specific survival (DSS), disease free survival (DFS) and overall survival (OS) of patients with HPV-related and non HPV-related vulvar SCC were compared.
RESULTS: In total 318 patients were included: 55 (17%) had HPV-related (Group 1) and 263 (83%) had non HPV-related vulvar SCC (Group 2). Tumors in Group 1 were significantly more often located at the perineum compared to Group 2, 30% and 14%, respectively (p=0.001). The DSS, DFS and OS were significantly better in HPV-related than in non HPV-related vulvar SCC patients.
CONCLUSION: HPV-related vulvar SCCs are more frequently located at the perineum and have a favorable prognosis compared to non HPV-related vulvar SCCs. Both localization and HPV-relation could explain this favorable prognosis. HPV-related vulvar SCC seems to be a separate entity.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Disease specific survival; Etiology; HPV; Human papillomavirus; Prognosis; Tumor localization; Vulvar cancer; p16(INK4a) expression

Mesh:

Year:  2018        PMID: 29555332     DOI: 10.1016/j.ygyno.2018.03.003

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  17 in total

Review 1.  New Directions in Vulvar Cancer Pathology.

Authors:  Anthony Williams; Sheeba Syed; Shireen Velangi; Raji Ganesan
Journal:  Curr Oncol Rep       Date:  2019-08-15       Impact factor: 5.075

2.  Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.

Authors:  Deyin Xing; Yuehua Liu; Hyeon Jin Park; Inji Baek; Hung Tran; Gloria Cheang; Jorge Novo; Jessica Dillon; Andres Matoso; Emily Farmer; Max A Cheng; Ya-Chea Tsai; Kara Lombardo; Michael G Conner; Russell Vang; Chien-Fu Hung; Tzyy-Choou Wu; Wei Song
Journal:  Hum Pathol       Date:  2019-08-19       Impact factor: 3.466

3.  Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status.

Authors:  Tjalling Bosse; Lynn N Hoang; Basile Tessier-Cloutier; Kim E Kortekaas; Emily Thompson; Jennifer Pors; Julia Chen; Julie Ho; Leah M Prentice; Melissa K McConechy; Christine Chow; Lily Proctor; Jessica N McAlpine; David G Huntsman; C Blake Gilks
Journal:  Mod Pathol       Date:  2020-03-20       Impact factor: 7.842

Review 4.  Molecular events in the pathogenesis of vulvar squamous cell carcinoma.

Authors:  Deyin Xing; Oluwole Fadare
Journal:  Semin Diagn Pathol       Date:  2020-09-25       Impact factor: 3.464

5.  Overexpression of p16INK4a Serves as Prognostic Marker in Squamous Cell Vulvar Cancer Patients Treated With Radiotherapy Irrespective of HPV-Status.

Authors:  Nathalie Arians; Elena-Sophie Prigge; Tereza Nachtigall; Miriam Reuschenbach; Stefan Alexander Koerber; Juergen Debus; Magnus von Knebel Doeberitz; Katja Lindel
Journal:  Front Oncol       Date:  2019-09-11       Impact factor: 6.244

6.  High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.

Authors:  Kim E Kortekaas; Saskia J Santegoets; Ziena Abdulrahman; Vanessa J van Ham; Marij van der Tol; Ilina Ehsan; Helena C van Doorn; Tjalling Bosse; Mariëtte I E van Poelgeest; Sjoerd H van der Burg
Journal:  J Immunother Cancer       Date:  2019-09-03       Impact factor: 13.751

7.  Lack of Conserved miRNA Deregulation in HPV-Induced Squamous Cell Carcinomas.

Authors:  Jaroslav Nunvar; Lucie Pagacova; Zuzana Vojtechova; Nayara Trevisan Doimo de Azevedo; Jana Smahelova; Martina Salakova; Ruth Tachezy
Journal:  Biomolecules       Date:  2021-05-20

8.  Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma.

Authors:  Kim E Kortekaas; Nienke Solleveld-Westerink; Basile Tessier-Cloutier; Tessa A Rutten; Mariëtte I E Poelgeest; C Blake Gilks; Lien N Hoang; Tjalling Bosse
Journal:  Histopathology       Date:  2020-06-07       Impact factor: 5.087

9.  The impact of p16ink4a positivity in invasive vulvar cancer on disease-free and disease-specific survival, a retrospective study.

Authors:  Lisa Gensthaler; Elmar A Joura; Laia Alemany; Reinhard Horvat; Silvia de Sanjosé; Sophie Pils
Journal:  Arch Gynecol Obstet       Date:  2020-01-22       Impact factor: 2.344

10.  The Clinical Relevance of p16 and p53 Status in Patients with Squamous Cell Carcinoma of the Vulva.

Authors:  Ellen L Barlow; Neil Lambie; Mark W Donoghoe; Zin Naing; Neville F Hacker
Journal:  J Oncol       Date:  2020-03-24       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.